title: Adherence to the 2007 cystic fibrosis pulmonary guidelines: a national survey of CF care centers.
abstract: OBJECTIVE
  To examine cystic fibrosis (CF) physician adherence to the 2007 CF Foundation (CFF) Pulmonary Guidelines for Chronic Medications. Specifically adherence and barriers to prescribing level A medication recommendations (i.e., inhaled tobramycin and dornase alfa) and level B medication recommendations (i.e., macrolide antibiotics and hypertonic saline) were studied.
  
  
  METHODS
  During Spring 2010, the CFF emailed survey invitations to directors of 136 accredited CF care centers treating 50+ CF patients. Directors were asked to forward the invitations to their physician colleagues. One hundred thirty-three surveys were included in the analyses, representing 92 centers. Barriers were conceptualized based on Cabana et al.'s framework for adherence to guidelines. Adherence was assessed via a case vignette.
  
  
  RESULTS
  Logistic regression analysis revealed that higher outcome expectancy (OR = 1.099, CI 1.010-1.196) and fewer environmental/system barriers (OR = 1.484, CI 1.158-1.902) were significantly associated with Vignette Adherence. A trend for an association between Familiarity and Vignette Adherence (OR = 1.642, CI 0.953-2.828) was evident, while no demographic variables were significantly associated with Vignette Adherence.
  
  
  CONCLUSIONS
  Targeting outcome expectancy and external barriers with multifaceted, ongoing interventions may improve guideline adherence. Pulmonologists are clearly looking for empirical evidence that these medications benefit their patients over the long-term and offset patient treatment burden with improved health.
authors.affiliation: CE Outcomes, LLC, Birmingham, Alabama, USA. terry.glauser@ceoutcomes.com
authors.forename: T A
authors.initials: TA
authors.lastname: Glauser
authors.forename: P H
authors.initials: PH
authors.lastname: Nevins
authors.forename: J C
authors.initials: JC
authors.lastname: Williamson
authors.forename: M
authors.initials: M
authors.lastname: Abdolrasulnia
authors.forename: G D
authors.initials: GD
authors.lastname: Salinas
authors.forename: J
authors.initials: J
authors.lastname: Zhang
authors.forename: L
authors.initials: L
authors.lastname: Debonnett
authors.forename: K A
authors.initials: KA
authors.lastname: Riekert
mesh_terms: D000293:Adolescent; D000328:Adult; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D001291:Attitude of Health Personnel; D002648:Child; D003550:Cystic Fibrosis / Q000150:complications / Q000628:therapy*; D003850:Deoxyribonuclease I / Q000627:therapeutic use; D005260:Female; D019983:Guideline Adherence / Q000706:statistics & numerical data*; D019538:Health Care Surveys / Q000706:statistics & numerical data*; D006801:Humans; D018942:Macrolides / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D017410:Practice Guidelines as Topic; D014031:Tobramycin / Q000627:therapeutic use; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D000900:Anti-Bacterial Agents; D018942:Macrolides; C085693:DNASE1 protein, human; D003850:Deoxyribonuclease I; D014031:Tobramycin